Beckman Coulter Dx EEMEA

🚀 Exciting News! 🚀 We are thrilled to announce the official signing of a Memorandum of Understanding (MoU) with Swiss Lab Saudi Arabia, during Global Health 2024 exhibition, marking a significant milestone in our ongoing collaboration. This partnership is crucial in making advanced diagnostic services more accessible and tailored to the local Jeddah population's needs. Our commitment extends to #Danaher #diagnostics latest products and technological advancements, starting with #Leica Diagnostics Solutions. This MoU signifies our shared vision of advancing healthcare through innovation and collaboration. We are eager to embark on this journey with Swiss Lab and are confident that together, we will achieve remarkable progress in the field of diagnostics. #HealthcareInnovation #Diagnostics #Partnership #SwissLab #Danaher #BeckmanCoulter #Collaboration #HealthcareExcellence

🧬 Decoding the Host Response to Infection. Sepsis can have devastating consequences. Timely administration of antibiotics is crucial, but unnecessary use can lead to antimicrobial resistance. Learn more about a comprehensive approach for better patient outcomes. 🔗 Download full infographic here: https://bit.ly/3AP5bxU #SepsisAwareness #HealthcareInnovation #AntibioticResistance #WorldSepsisDay #Diagnostics

🚨 CLIA 2024 changes are here. Are you over three? At six? The goals have tightened, and assays with < 3 sigma performance are in greater danger of failing proficiency testing. An independent study from WESTGARD QC presented at ADLM 2024 independently analyzed several assays on the DxI 9000 Immunoassay Analyzer* and found they hit the mark. 💡 Read the study here: https://bit.ly/4gAlz5B *Full name: DxI 9000 Access Immunoassay Analyzer

Alzheimer's disease is the most common form of dementia, and its prevalence is expected to rise in the coming years as the global population ages. This trend makes Alzheimer's an increasingly critical global public health issue. The emerging and rapidly evolving treatment landscape, particularly with disease-modifying therapies, holds promise for potentially changing the course of the disease and improving long-term outcomes for patients. Learn about the challenges in diagnosing Alzheimer's disease and the emerging treatment landscape: https://bit.ly/3YCMoOL #AlzheimersAwareness #NeurologicalResearch #Dementia #DiagnosticTesting #NeurologicalDiseaseBiomarkerResearch

Parathyroid hormone (PTH) is essential for healthy calcium levels. Its imbalance can lead to: ▪ Hyperparathyroidism: Affects 1-7 in 1,000 people, especially women over 50, increasing osteoporosis risk and potentially causing renal osteodystrophy. ⚠️ ▪ Hypoparathyroidism: Impacts 24-37 in 100,000 people, resulting in muscle cramps and bone density loss. 💔 ▪ Hypercalcemia of Malignancy: Occurs in 20-30% of cancer patients, risking heart, kidney, and bone health. 🦴 At Beckman Coulter Diagnostics, our bone health menu empowers clinicians with advanced diagnostics to identify and manage these conditions effectively, supporting healthier lives worldwide. #BoneHealth #BoneHealthMenu #BoneHealthMatters #PTH #Hyperparathyroidism #Hypoparathyroidism #Hypercalcemia #Osteoporosis

🚨 CLIA 2024 changes are here. Are you over three? At six? The goals have tightened, and assays with < 3 sigma performance are in greater danger of failing proficiency testing. An independent study from WESTGARD QC presented at ADLM 2024 independently analyzed several assays on the DxI 9000 Immunoassay Analyzer* and found they hit the mark. 💡 Read the study here: https://bit.ly/4gAlz5B *Full name: DxI 9000 Access Immunoassay Analyzer

🌍 Wrapping up an incredible MedLab Africa 2024! A heartfelt thank you to our customers, partners, and associates for making this event a success. Beckman Coulter showcased the latest innovations and led insightful panel discussions on critical healthcare advancements. From engaging discussions to hands-on demos, your enthusiasm and engagement made it all possible. Here’s a look back at the event highlights! 🎥 #MedLabAfrica #BeckmanCoulter #HealthcareInnovation #Diagnostics #AfricaHealthcare #StrongerTogether #ThankYou #BestTeamWins

🎗️ This October, let’s unite to raise awareness about breast cancer, the most common cancer globally, with 2.3 million new cases annually. It represents 1 in 8 cancer cases and a quarter of all cancers in women, with 70% of mortality in resource-limited settings. At Beckman Coulter, we’re committed to providing diagnostic solutions that empower healthcare professionals in the fight against breast cancer. 🩺 Early detection and 🔬 advanced diagnostics are key to improving outcomes. Join us—because no one should face breast cancer alone. 💗🎀 #BreastCancerAwareness #EarlyDetection #DiagnosticsForLife #SupportTheFight #WomenHealth #ThinkPink #Cancer

After Osteoporosis Awareness Day, we continue to raise awareness about bone health. Today, we focus on Paget’s disease of bone, a common skeletal disorder characterized by abnormal bone cell activity. While often asymptomatic, it can cause pain, fractures, and deformities. Globally, Paget’s disease is the second most prevalent bone disorder after osteoporosis, affecting 1–2% of people over 55 👩🦳👨🦳. Early detection and treatment are crucial for better outcomes 🩺. At Beckman Coulter Diagnostics, we are dedicated to a future with No More Broken Bones, No More Broken Lives 💪🦴. Learn more ➡️ https://lnkd.in/d_NrNqMX #BoneHealth #PagetsDisease #GlobalHealth #NoMoreBrokenBones #Osteoporosis #PatientCare

🚨 CLIA 2024 changes are here. Are you over three? At six? The goals have tightened, and assays with < 3 sigma performance are in greater danger of failing proficiency testing. An independent study from WESTGARD QC presented at ADLM 2024 independently analyzed several assays on the DxI 9000 Immunoassay Analyzer* and found they hit the mark. 💡 Read the study here: https://bit.ly/4gAlz5B *Full name: DxI 9000 Access Immunoassay Analyzer